Karen L. Tubridy, Pharm.D., has been appointed chief development officer at Eleven Biotherapeutics. Ms. Tubridy will be responsible for leading and executing the company’s clinical and regulatory development strategy focused on innovative protein therapeutics for ocular diseases, in particular, the company’s lead candidate, EBI-005. Ms. Tubridy will be a member of Eleven’s management team reporting to Abbie Celniker, Ph.D., chief executive officer.   Ms. Tubridy has more than 20 years of experie...